Kenvue

Kenvue

Personal Care Products
Kenvue is the world’s largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.

$34.3B

Market Cap • 9/22/2026

2022

(4 years)

Founded

2023

(3 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

S&P500 Participant

Index Composite • 2026

Valuation

P/B

3,3

P/S

2,2

P/EBITDA

10,7

P/OCF

14,8

P/FCF

17,9

P/E

20,5

BVPS

5,5

EPS

0,9

Market Cap

Market Cap

34,3B

EV

41,7B

EV/Revenue

2,7

EV/EBITDA

13

EV/EBIT

15,8

Payout

Dividend Per Share

0,8

Dividend Yield

4,6%

Buyback Yield

0%

Total Yield

4,6%

Dividend Yield 5Y

4%

Payout

96%

Retained Earnings

-70M

Profitability

Gross Margin

58,2%

EBITDA Margin

20,7%

EBIT Margin

17,1%

Net Margin

10,8%

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

2,7%

Capex/D&A

72,5%

Capex/OCF

17,7%

SBC/OCF

5%

% PPE

8,3%

% Goodwill

34,7%

ROE

15,6%

ROIC

8,7%

Leverage

N.D./EBITDA

2,3

Debt/Equity

0%

Current Ratio

1

Quick Ratio

0,7

Interest Coverage

699,5%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium